Covaxin proves 77.8% efficient in third phase trial

Bharat Biotech manufactures Covaxin, which is used to treat the covid19 disease. In January, it was granted permission to be utilised for emergency purposes.

It was found to be 77.8% effective against covid19 illness after its third phase studies.

Bharat Biotech released these safety and efficacy updates from phase three trials on Saturday. This vaccine was developed in collaboration with the Indian Council of Medical Research and the National Institute of Virology in Pune, India.

Around 25,800 people took part in the third phase of covaxin trials, which demonstrated that the vaccination was well tolerated.

After the second dosage, this vaccine was found to be 81 per cent effective in preventing covid19 infection in people who had not previously been infected. Final 130 applicants infected with covid19 were enrolled in the clinical experiment.

With trials and investigations conducted in 25 centres across India, the vaccine has shown 93 per cent efficacy in severe instances. This was India’s largest third-phase study

In the vaccine groups, 24 infections occurred out of 130 affected patients.Researchers have requested trials on various strains of a disease that is sweeping India.

In a statement released on Saturday, Dr Krishna Ella, Chairman and Managing Director of Bharat Biotech International Limited (BBIL), said, “The safety profile of COVAXIN is now well established based on inactivated vaccine technology, and in large part due to the extensive 20-year safety track record of Bharat Biotech’s Vero cell manufacturing platform.”

He went on to say that they are proud of India’s innovation, which would be available to protect the world’s people.

So far, Covaxin has gained emergency use authorisation (EUA) in 16 countries, with EUAs in the works in another 50. Covaxin is also being discussed with the World Health Organization (WHO) in order to achieve an Emergency Use Listing.